IDRA News Alert Idera Pharmaceuticals (IDRA) 4.06 12/04/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 4, 2014 at 6:30 PM

Idera Pharmaceuticals (IDRA) 4.06 $IDRA

Hawaiian Electric and Taser are big market movers
AP - 1 hr 54 mins ago
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
TSLA: 228.28 (-1.02), HE: 32.22 (+4.03), PLUG: 3.70 (+0.20), CLV: 7.55 (-0.60), CLF: 8.03 (-0.57), BKS: 21.03 (-1.21), ARO: 2.48 (-0.71), RAD: 5.58 (+0.12), CARB: 14.21 (-0.23), SQNM: 3.67 (-0.10), ENB.TO: 60.04 (+5.61), RIG: 18.68 (-0.89), IDRA: 4.06 (-0.01), ANF: 27.90 (-0.91), ENB: 52.80 (+4.92), TASR: 24.15 (+1.29), AVGO: 103.07 (+7.94), PBYI: 195.55 (-2.12)

Traders Get Bullish on Shares of Idera Pharmaceuticals, Shares Up 7.0% (IDRA)
Comtex SmarTrend(R) - Wed Dec 03, 10:36AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's best performing low-priced stocks, up 7.0% to $3.83 on 3.7x average daily volume. Idera Pharmaceuticals has traded 2.7 million shares thus far today, vs. average volume of 727,000 shares per day. The stock has outperformed the Dow (7.0% to the Dow's 0.1%) and outperformed the S&P 500 (7.0% to the S&P's 0.2%) during today's trading.
IDRA: 4.06 (-0.01)

Idera up on preclinical data
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 9:47AM CST

IDRA: 4.06 (-0.01)

Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated Potent and Systemic Anti-Tumor Activity in Preclinical Models
GlobeNewswire - Tue Dec 02, 3:30PM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced new preclinical data that showed cancer immunotherapy with intratumoral injections of IMO-2055 and ipilimumab demonstrated potent and systemic anti-tumor activity in multiple preclinical cancer models. IMO-2055 is a synthetic oligonucleotide-based agonist of Toll-like receptor (TLR) 9 discovered and developed by Idera. Ipilimumab is a checkpoint inhibitor targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The data were presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Meeting in Orlando, Fla., earlier today.
IDRA: 4.06 (-0.01)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 11:47AM CST

CY: 12.48 (-0.03), QDEL: 24.01 (+0.22), WLT: 1.78 (-0.08), VNCE: 29.73 (-0.25), ISNS: 3.06 (+0.07), VII: 1.56 (-0.07), NTLS: 4.56 (+0.01), MFRM: 62.07 (-1.47), GSAT: 2.71 (-0.03), MOLG: 2.85 (-1.05), EVOK: 5.92 (-0.13), IDRA: 4.06 (-0.01), SCVL: 23.77 (+0.53), VGGL: 3.68 (-0.34), MIXT: 7.45 (-0.05), ENVI: 1.25 (+0.01), REI: 9.34 (+0.42), TRX: 0.88 (-0.01), DGLY: 21.00 (+3.08), CODE: 29.01 (+0.15)

Idera Announces Appointment of Robert A. Doody Jr. as Vice President of Investor Relations and Corporate Communications
GlobeNewswire - Tue Dec 02, 9:50AM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases, announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations and Corporate Communications.
IDRA: 4.06 (-0.01)

Idera Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Dec 02, 7:30AM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing novel nucleic acid therapeutics for cancer and rare diseases, today announced that Company management will present at the 26 Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 3:30 p.m. EST in New York.
IDRA: 4.06 (-0.01)

Idera Pharmaceuticals Names Vincent J. Milano Chief Executive Officer
GlobeNewswire - Mon Dec 01, 5:06PM CST
-- Appointment brings commercial, operational and financial expertise
IDRA: 4.06 (-0.01), VNDA: 12.27 (-0.38)

New Chief at Idera
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 3:54PM CST

IDRA: 4.06 (-0.01)

Idera Pharmaceuticals (IDRA) Is Today's Strong On High Volume Stock
at The Street - Fri Nov 28, 9:03AM CST
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a strong on high relative volume candidate
IDRA: 4.06 (-0.01)

Idera Pharmaceuticals: A Star In The Making
Samreen Agha - at Seeking Alpha - Wed Nov 26, 11:46AM CST

IDRA: 4.06 (-0.01)

Hot Stock: Idera Pharmaceuticals, Shares Gain 8.2% (IDRA)
Comtex SmarTrend(R) - Wed Nov 26, 10:05AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's best performing low-priced stocks, up 8.2% to $3.03 on 2.5x average daily volume. Idera Pharmaceuticals has traded 1.7 million shares thus far today, vs. average volume of 665,000 shares per day. The stock has outperformed the Dow (8.2% to the Dow's -0.1%) and outperformed the S&P 500 (8.2% to the S&P's 0.1%) during today's trading.
IDRA: 4.06 (-0.01)

Are Central Banks Panicking?
Leo Kolivakis - Seeking Alpha - Fri Nov 21, 12:50PM CST
Koh Gui Qing and Jason Subler of Reuters report, China surprises with interest rate cut to spur growth : China cut interest rates unexpectedly on Friday, stepping up efforts to support the world's second-biggest economy as it heads towards its...
PGNX: 7.25 (+0.15), BCRX: 9.92 (-0.66), AVNR: 16.96 (+0.04), ACAD: 30.46 (+0.05), IDRA: 4.06 (-0.01), QQQ: 105.37 (-0.05), SGEN: 36.50 (-0.91), XBI: 178.11 (-1.37), TGTX: 13.84 (-0.58), IBB: 306.20 (-2.05), THLD: 3.00 (+0.05), IWM: 116.81 (-0.56), TWTR: 38.79 (-0.27), XOMA: 4.46 (-0.30)

Idera Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Thu Nov 13, 7:30AM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing novel nucleic acid therapeutics for rare diseases, today announced that Company management will present at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 4:10 p.m. EST in New York.
IDRA: 4.06 (-0.01)

Idera Pharmaceuticals' (IDRA) CEO Sudhir Agrawal on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 10:52PM CST

IDRA: 4.06 (-0.01)

Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST

CANF: 4.04 (-0.23), JNJ: 107.56 (-0.16), IDRA: 4.06 (-0.01), DERM: 17.22 (+0.13), MRK: 60.92 (+0.34), PFE: 31.67 (-0.08), AZN: 73.94 (+0.12), AMGN: 166.55 (-1.52), GSK: 45.89 (-0.82), HSP: 59.26 (-0.48), NVS: 95.77 (+0.11), CELG: 113.63 (-0.60)

Idera ups revenues 329% in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:00AM CST

IDRA: 4.06 (-0.01)

Idera Pharmaceuticals EPS in-line
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:13AM CST

IDRA: 4.06 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Termite Swarmers: Essential Clues and Action Steps

Understanding the Intrusive Nature of Termite Swarmers When it comes to creepy crawlies wreaking havoc on your beloved abode, termites are the stealthy troublemakers you need to keep an eye out for. Just because you catch a glimpse of them doesn't mean the damage is obvious or minimal. Spotting the Culprits: Termites vs. Ants Identifying what you're up against is the...

Allegiant Overhauls Service with UNLV Training

Allegiant Airlines and UNLV: A Unique Collaboration The world of airline customer service is about to get a shakeup, thanks to a new collaboration between Allegiant Airlines and the University of Nevada, Las Vegas' renowned William F. Harrah College of Hospitality. It's a partnership that aims to bring a new level of service to the skies, guided by some of the best minds...

Sinopec Unveils Biodiversity Report at COP17

Sinopec's First Step on the Global Biodiversity Stage Seems like Sinopec (HKG: 0386) has decided to toss its hat into the biodiversity conservation ring. At COP17 in Armenia, they released their inaugural Global Biodiversity Conservation Report—an event that marks more than just a company selling oil and gas. Now, they're talking wildlife and ecologies. Is that irony,...

Muyang Group's High-Stakes Legal Battle Over Corporate Sabotage

Decades of Corporate Drama Unfold in Court A pesky legal storm is brewing from the heart of Yangzhou, China, as Jiangsu Muyang Group battles former execs in a lawsuit that reeks of corporate intrigue. You can't make this stuff up—downright Shakespearean treachery unfolding at a feed machinery powerhouse! Muyang's courtroom escapades haven't exactly flown under the...

Veteran Surge in 2026 Midterm Elections: A New Wave

A Swell of Veteran Candidates Hits the Midterm Shores Just when you think you've seen it all in politics, here comes another twist. As the 2026 midterms gear up, an impressive 258 military veterans are throwing their hats into the congressional ring. That's a jump up from 213 just two years back, and let me tell you, it's not just a numbers game—it's a sea change. Women...

Investcorp's Strong 2026: A Deep Dive into Key Moves

Diving into Investcorp's Robust 2026 Performance If you're clued into the investment scene, you'll know that a $65.2 billion asset base isn't small potatoes. At the Gateway Gulf 2026, Investcorp didn't just present numbers—they laid out a dramatic year of action packed with billion-dollar dreams. While the dust hasn't quite settled yet, the first nine months of the year...

Aosom Unveils Its Boldest Black Friday Extravaganza

Black Friday Heat Kicks Off Early at Aosom All the seasoned shoppers out there smell a deal from a mile away, and Aosom isn't taking any chances by launching their Black Friday bash smack dab on November 2nd. This isn’t just any sale, it’s shaping up to be their most gigantic festival of discounts yet. Across Europe and North America, folks are rubbing their hands...

2026 Rawlings Gold Glove Award Winners Announced

Fielding Excellence on Display: The 2026 Rawlings Gold Glove Awards The Rawlings Gold Glove Awards have once again shone the spotlight on baseball's defensive maestros. Announced by Rawlings Sporting Goods Company, Inc., on November 1, 2026, this year's winners include 11 seasoned veterans and nine greenhorns who claimed their first-ever Gold Gloves. Unveiled during a...

FFR Sets New Sales Record, Eyes Market Expansion

FFR Breaks New Ground With Record Sales Something big's brewing at FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR), and it's causing quite the ripple. Picture this: 351 devices shipped in October alone. That's a hill-climbing record for this newbie on the U.S. stock scene. February was their starting line, and they've zoomed past 1,000 units in cumulative sales, chalking up...

Navigating the Maze of Required Minimum Distributions

Understanding Required Minimum Distributions Ever felt like retirement planning is walking a financial tightrope? Well, when it comes to Required Minimum Distributions (RMDs), you're tiptoeing on a wire. These IRS-mandated withdrawals aren't just accounting quirks; they’re a cornerstone of retirement income strategy—a fact unmistakably highlighted by Janie Kelly in...